Genmab — August 2019

[E_L]

another Dara abstract - OAB-060
A Prospective Phase II of Daratumumab in
Previously Treated Systemic Light-Chain
(AL) Amyloidosis: Updated Results

[E_L]

CONCLUSIONS: Monotherapy with
DARA demonstrates encouraging efficacy in
previously treated pts with AL amyloidosis with
deep and rapid hematological responses with a good
safety profile. The Andromeda phase 3 study
comparing CyborD with or without DARA is
ongoing.

[Sukkeralf]

Lets hope Andromeda interim data read out in late 2019 will be positive

[Sukkeralf]

It could be rather cool if both ofatumumab in MS and daratumumab in Amyloidosis and teprotumumab in TED all get on the market - then its suddenly quit a bit more income in the coming years¨

[E_L]

and then a a CD3xCD20 deal to top it off early next year

[E_L]

FP-117
Preclinical evaluation of the new
GPRC5DxCD3 (JNJ-7564) bispecific
antibody for the treatment of multiple
myeloma

[E_L]

Conclusion: GPRC5D
is highly and selectively expressed on MM cells,
which makes it an attractive therapeutic target. The
GPRC5DxCD3 bispecific antibody, JNJ-7564,
effectively lysed MM cell lines and primary MM
cells in samples derived from both newly diagnosed
and heavily pretreated patients, including DARArefractory patients.

[Sukkeralf]

Nothing about the BCMA/CD3 antibody?

[E_L]

FP-149
Safety of rapid daratumumab infusion in
relapsed and refractory multiple myeloma

[E_L]

Daratumumab infusion
time of 90 minutes was well tolerated, thus allowing
a considerable saving of time for RRMM patients
and potentially ameliorating their adherence to
treatment

[E_L]

i am still searching for interesting Dara hits, there are 289 in that book, so bear with me

[Solsen]

The AMG420 are also in the abstracts although it seems to be stopped.

[E_L]

FP-155
DNA methyltransferase inhibitors upregulate
CD38 expression and enhance daratumumab
efficacy in multiple myeloma

[E_L]

Summary and Conclusions: Our
results here demonstrate that inhibiting DNMTs
leads to CD38 upregulation and increased
vulnerability to Daratumumab treatment. We
propose that combination treatment with

[E_L]

Azacytidine and Daratumumab can lead to higher
efficacy of daratumumab in daratumumab-naïve
MM, as well as reversal of daratumumab-resistance.
We are currently planning a clinical trial to test this
hypothesis.

[E_L]

a bit like ATRA as we have seen before? i expect more and more trials based on Dara by other firms

[Bulder]

In my notes I have 5 other drugs supporting c38 expression. ATRA, Sepantronium bromide (YM155), Panobinostat og SY-1425 (tamibarotene) and Inecalcitol. This must be no 6. I think ATRA has been given up more or less?

[E_L]

your notes are better then mine I think there is still an ATRA-Dara trial open, but indeed, Jan at some point said there are better options

[E_L]

ATRA was a bit toxic, wasnt it

[E_L]

FP-162 says costs associated with
rapid infusion vs normal infusion do not differ much. I am a bit surprised by that.